Latest Breaking News On - Centessa pharmaceuticals - Page 7 : comparemela.com

BMO Capital Markets reissued their outperform rating on shares of Centessa Pharmaceuticals (NASDAQ:CNTA – Free Report) in a research report report published on Monday morning, Benzinga reports. BMO Capital Markets currently has a $15.00 price objective on the stock. Centessa Pharmaceuticals Stock Performance Shares of CNTA stock opened at $10.37 on Monday. The business has […]

Karenm andersonHarris rotmanSusquehanna international groupHedge funds weigh in on centessa pharmaceuticalsAnalyst recommendations for centessa pharmaceuticalsCentessa pharmaceuticals stock performanceCentessa pharmaceuticals company profileNews ratings for centessa pharmaceuticals dailyChina universal asset management coBarclays plcCentessa pharmaceuticalsJpmorgan chase coFree reportInternational groupChina universal asset managementUniversal asset management